JPMorgan Chase & Co’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $88K | Buy |
18,723
+2,597
| +16% | +$12.2K | ﹤0.01% | 4845 |
|
|
2025
Q1 | $58.9K | Sell |
16,126
-40,405
| -71% | -$147K | ﹤0.01% | 4977 |
|
|
2024
Q4 | $267K | Buy |
56,531
+45,565
| +416% | +$215K | ﹤0.01% | 4420 |
|
|
2024
Q3 | $102K | Sell |
10,966
-87
| -0.8% | -$810 | ﹤0.01% | 4717 |
|
|
2024
Q2 | $63.6K | Sell |
11,053
-2,985
| -21% | -$17.2K | ﹤0.01% | 4815 |
|
|
2024
Q1 | $94.2K | Buy |
14,038
+862
| +7% | +$5.78K | ﹤0.01% | 4756 |
|
|
2023
Q4 | $85K | Sell |
13,176
-7,841
| -37% | -$50.6K | ﹤0.01% | 4837 |
|
|
2023
Q3 | $105K | Buy |
21,017
+3,921
| +23% | +$19.6K | ﹤0.01% | 4573 |
|
|
2023
Q2 | $120K | Buy |
17,096
+1,596
| +10% | +$11.2K | ﹤0.01% | 4554 |
|
|
2023
Q1 | $96K | Buy |
15,500
+4,125
| +36% | +$25.5K | ﹤0.01% | 4665 |
|
|
2022
Q4 | $73K | Buy |
11,375
+395
| +4% | +$2.54K | ﹤0.01% | 4605 |
|
|
2022
Q3 | $94K | Buy |
10,980
+236
| +2% | +$2.02K | ﹤0.01% | 4488 |
|
|
2022
Q2 | $146K | Buy |
10,744
+1,570
| +17% | +$21.3K | ﹤0.01% | 4463 |
|
|
2022
Q1 | $140K | Buy |
9,174
+1,664
| +22% | +$25.4K | ﹤0.01% | 4612 |
|
|
2021
Q4 | $172K | Sell |
7,510
-4,192
| -36% | -$96K | ﹤0.01% | 4609 |
|
|
2021
Q3 | $163K | Sell |
11,702
-14,533
| -55% | -$202K | ﹤0.01% | 4499 |
|
|
2021
Q2 | $280K | Buy |
26,235
+6,224
| +31% | +$66.4K | ﹤0.01% | 4326 |
|
|
2021
Q1 | $264K | Buy |
20,011
+372
| +2% | +$4.91K | ﹤0.01% | 4348 |
|
|
2020
Q4 | $399K | Buy |
+19,639
| New | +$399K | ﹤0.01% | 3871 |
|